A5030232317- Phagocytosis and Immune Regulation
- Chronic Myeloid Leukemia Treatments
- Chronic Lymphocytic Leukemia Research
- Pancreatic and Hepatic Oncology Research
- Prostate Cancer Treatment and Research
- Cancer Cells and Metastasis
- Cancer Genomics and Diagnostics
- Protein Degradation and Inhibitors
- Epigenetics and DNA Methylation
- Immunotherapy and Immune Responses
- Renal cell carcinoma treatment
- Cancer Mechanisms and Therapy
- Renal and related cancers
- Neuroblastoma Research and Treatments
- HER2/EGFR in Cancer Research
- Platelet Disorders and Treatments
- Monoclonal and Polyclonal Antibodies Research
- Cancer-related gene regulation
- Complement system in diseases
- Receptor Mechanisms and Signaling
- RNA modifications and cancer
- 14-3-3 protein interactions
University of Wisconsin Carbone Cancer Center
2018-2022
University of Wisconsin–Madison
2016-2022
Highland Community College - Illinois
2021
Madison Group (United States)
2017
Tumor cells initiate platelet activation leading to the secretion of bioactive molecules, which promote metastasis. Platelet receptors on tumors have not been well-characterized, resulting in a critical gap knowledge concerning platelet-promoted We identify direct interaction between platelets and tumor CD97 that stimulates rapid bidirectional signaling. CD97, an adhesion G protein-coupled receptor (GPCR), is overexpressed antigen several cancer types. Purified extracellular domain or...
Downregulation of HLA class I (HLA-I) impairs immune recognition and surveillance in prostate cancer may underlie the ineffectiveness checkpoint blockade. However, molecular mechanisms regulating HLA-I loss have not been fully explored. Here, we conducted a comprehensive analysis genomic, epigenomic gene expression alterations primary metastatic human cancer. Loss was associated with repressive chromatin states including DNA methylation, histone H3 tri-methylation at lysine 27, reduced...
Abstract Purpose: Radiation and cetuximab are therapeutics used in management of head neck squamous cell carcinoma (HNSCC). Despite clinical success with these modalities, development both intrinsic acquired resistance is an emerging problem the this disease. The purpose study was to investigate signaling receptor tyrosine kinase AXL radiation treatment. Experimental Design: To context treatment-resistant HNSCC, we patient-derived xenografts (PDXs) implanted into mice evaluated tumor...
Although therapeutic options for patients with advanced renal cell carcinoma (RCC) have increased in the past decade, no biomarkers are yet available patient stratification or evaluation of therapy resistance. Given dynamic and heterogeneous nature clear RCC (ccRCC), tumor biopsies provide limited clinical utility, but liquid could overcome these limitations. Prior biopsy approaches lacked clinically relevant detection rates ccRCC. This study employed ccRCC-specific markers, CAIX CAXII, to...
Prostate Cancer (PC) is a disease with remarkable tumor heterogeneity that often manifests in significant intra-patient variability regards to clinical outcomes and treatment response. Commonly available PC cell lines do not accurately reflect the complexity of this there critical need for development new models recapitulate intricate hierarchy pathogenesis. In current study, we established ex vivo primary patient-derived cancer organoid (PDCO) cultures from prostatectomy specimens patients...
DNA methylation alterations have emerged as hallmarks of cancer and been proposed screening, prognostic, predictive biomarkers. Traditional approaches for analysis relied on bisulfite conversion DNA, which can damage is not suitable targeted gene in low-input samples. Here, we adapted methyl-CpG-binding domain protein 2 (MBD2)-based enrichment use a semi-automated exclusion-based sample preparation (ESP) platform robust scalable methylated from samples, called SEEMLIS. We show that combining...
Abstract DNA damage response (DDR) is an important cellular process that regulated by poly ADP ribosylation (PARylation). PARP1 binds to break sites and then catalyzes PARylation, which leads recruitment of repair factors initiation base-excision single-strand (SSB) repair. Removal PAR chains performed PARG also critical for successful completion Suppression chain hydrolysis via depletion or inhibition defective repair, reduced kinetics hypersensitivity certain damaging agents. Cancer cells...
4579 Background: New therapeutic strategies and biomarkers of treatment resistance are needed for metastatic ccRCC patients (pts) progressing on Nivolumab (Nivo). The upcoming OMNIVORE phase II clinical trial will evaluate whether adding Ipilumimab improves rPFS pts with SD or PD Nivo alone. We report development validation predictive CTC that be evaluated in the trial. Methods: tested blood samples from collected biomarker trials at Dana Farber U. Wisconsin. Carbonic Anhydrase (CA) IX was...
Abstract Radiation and cetuximab are therapeutics used in the management of head neck squamous cell carcinoma (HNSCC). Despite clinical success with these modalities, development both intrinsic acquired resistance is an emerging problem this disease. Thus, identifying targeting molecules that drive to radiation or essential for improving efficacy treatment approaches. Previously, we identified AXL as a logical molecular target HNSCC indicated it may play pivotal role cetuximab. In our...
<p>Apoptotic bodies in treatment studies</p>
<div>AbstractPurpose:<p>Radiation and cetuximab are therapeutics used in management of head neck squamous cell carcinoma (HNSCC). Despite clinical success with these modalities, development both intrinsic acquired resistance is an emerging problem the this disease. The purpose study was to investigate signaling receptor tyrosine kinase AXL radiation treatment.</p>Experimental Design:<p>To context treatment-resistant HNSCC, we patient-derived xenografts (PDXs)...
<p>Ctx+R428 in HN30-AXL-Y821F</p>
<p>siABL1+R428+Ctx in HN30-AXL WT</p>
<p>Synergy analysis of treatment studies using fractional product method</p>
<p>Clinical characteristics of tumors</p>
<p>Clinical characteristics of tumors</p>
<p>Figure legends to accompany supplemental data</p>
<p>ABL targeting in cetuximab-resistant clones</p>
<p>ABL targeting in cetuximab-resistant clones</p>
<div>AbstractPurpose:<p>Radiation and cetuximab are therapeutics used in management of head neck squamous cell carcinoma (HNSCC). Despite clinical success with these modalities, development both intrinsic acquired resistance is an emerging problem the this disease. The purpose study was to investigate signaling receptor tyrosine kinase AXL radiation treatment.</p>Experimental Design:<p>To context treatment-resistant HNSCC, we patient-derived xenografts (PDXs)...
<p>Ctx+R428 in HN30-AXL-Y821F</p>
<p>Ki67 staining in additional models</p>
<p>Ki67 staining in additional models</p>
<p>siABL1+R428+Ctx in HN30-AXL WT</p>